Clinical Trial Update: Dose Escalation Study of BIBF 1120 in Combination With Carboplatin and PLD in Relapsed Ovarian Cancer (OC) [Phase 1]

View source ↗

Summary

A Phase 1 dose-escalation trial evaluated BIBF 1120 in combination with carboplatin and pegylated liposomal doxorubicin in relapsed ovarian cancer; the study wa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• BIBF 1120 (nintedanib)
• CARBOPLATIN (Carboplatin)
• Pegylated liposomal doxorubicin (pegylated liposomal doxorubicin)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Ovarian Neoplasms | Phase 1 | Status: TERMINATED | Results posted: 2014-11-27